Přístupnostní navigace
E-přihláška
Vyhledávání Vyhledat Zavřít
Detail publikace
ŠMÍDOVÁ, V. MICHÁLEK, P. GOLIÁŠOVÁ, Z. ECKSCHLAGER, T. HODEK, P. ADAM, V. HEGER, Z.
Originální název
Nanomedicine of tyrosine kinase inhibitors
Typ
článek v časopise ve Web of Science, Jimp
Jazyk
angličtina
Originální abstrakt
Recent progress in nanomedicine and targeted therapy brings new breeze into the field of therapeutic applications of tyrosine kinase inhibitors (TKIs). These drugs are known for many side effects due to non-targeted mechanism of action that negatively impact quality of patients' lives or that are responsible for failure of the drugs in clinical trials. Some nanocarrier properties provide improvement of drug efficacy, reduce the incidence of adverse events, enhance drug bioavailability, helps to overcome the blood-brain barrier, increase drug stability or allow for specific delivery of TKIs to the diseased cells. Moreover, nanotechnology can bring new perspectives into combination therapy, which can be highly efficient in connection with TKIs. Lastly, nanotechnology in combination with TKIs can be utilized in the field of theranostics, i.e. for simultaneous therapeutic and diagnostic purposes. The review provides a comprehensive overview of advantages and future prospects of conjunction of nanotransporters with TKIs as a highly promising approach to anticancer therapy.
Klíčová slova
Bioavailability; Drug delivery; Nanotechnology; Targeted therapy
Autoři
ŠMÍDOVÁ, V.; MICHÁLEK, P.; GOLIÁŠOVÁ, Z.; ECKSCHLAGER, T.; HODEK, P.; ADAM, V.; HEGER, Z.
Vydáno
26. 1. 2021
Nakladatel
Ivyspring
ISSN
1838-7640
Periodikum
Theranostics
Ročník
11
Číslo
4
Stát
Australské společenství
Strany od
1546
Strany do
1567
Strany počet
22
URL
https://www.thno.org/v11p1546.htm
Plný text v Digitální knihovně
http://hdl.handle.net/11012/196698
BibTex
@article{BUT168341, author="Veronika {Šmídová} and Petr {Michálek} and Zita {Goliášová} and Tomáš {Eckschlager} and Petr {Hodek} and Vojtěch {Adam} and Zbyněk {Heger}", title="Nanomedicine of tyrosine kinase inhibitors", journal="Theranostics", year="2021", volume="11", number="4", pages="1546--1567", doi="10.7150/thno.48662", issn="1838-7640", url="https://www.thno.org/v11p1546.htm" }